Ownership and insider activity for Liquidia Corporation (LQDA): recent transactions by executives and directors. Track how corporate insiders are trading the stock.
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension.
Price
| Price | $47.38 (closing price, November 4, 2026) |
| Market Cap | $4.2B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-10-26 | Boyle Dana | S-Sale | 1,581 | $68K |
| 2026-10-26 | Adair Jason | S-Sale | 688 | $30K |
| 2026-10-09 | Schundler Russell | M-Exempt | 6,409 | |
| 2026-10-09 | Schundler Russell | M-Exempt | 3,758 | |
| 2026-10-12 | Schundler Russell | S-Sale | 13,692 | $390K |
| 2026-10-09 | Schundler Russell | M-Exempt | 6,409 | |
| 2026-10-09 | Schundler Russell | M-Exempt | 3,758 | |
| 2026-10-09 | Saggar Rajeev | M-Exempt | 4,486 | |
| 2026-10-09 | Saggar Rajeev | M-Exempt | 3,530 | |
| 2026-10-12 | Saggar Rajeev | S-Sale | 9,218 | $263K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.4M | $3.4M | $39.5M | $55.8M | $65.3M | $57.5M | $93.3M | $83.7M | $176.5M | $190.7M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $1.2M | $1.6M | $272,557 | 0 | 0 | $3.0M | $5.0M | $4.1M | $2.7M | $54.1M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $241,000 | 0 |
| Total Current Assets | $3.1M | $5.5M | $40.0M | $56.4M | $66.1M | $61.3M | $99.8M | $89.9M | $185.1M | $190.7M |
| Property, Plant & Equipment | $4.3M | $8.2M | $8.1M | $12.1M | $9.5M | $7.4M | $6.3M | $6.2M | $12.5M | 0 |
| Goodwill | 0 | 0 | 0 | 0 | $3.9M | $3.9M | $3.9M | $3.9M | $3.9M | $3.9M |
| Intangible Assets | 0 | 0 | 0 | 0 | $5.5M | $4.4M | $3.7M | $3.4M | $3.2M | $3.0M |
| Total Assets | $8.5M | $14.8M | $49.4M | $68.8M | $99.5M | $93.7M | $129.2M | $118.3M | $230.3M | $327.9M |
| Accounts Payable | $2.4M | $4.4M | $3.2M | $3.5M | $3.7M | $1.1M | $2.2M | $1.4M | $4.7M | $3.7M |
| Short-term Debt | $2.9M | $15.6M | $316,906 | $5.6M | 0 | 0 | 0 | $2.6M | $18.0M | $58.4M |
| Total Current Liabilities | $12.1M | $30.5M | $8.2M | $16.9M | $11.7M | $7.3M | $8.8M | $18.6M | $41.8M | $135.8M |
| Long-term Debt | $5.2M | $5.6M | $11.6M | $10.3M | $10.3M | $10.4M | $19.9M | $43.4M | $97.4M | $132.9M |
| Total Liabilities | $26.7M | $48.5M | $30.7M | $33.9M | $28.4M | $28.5M | $38.8M | $71.0M | $153.0M | $283.2M |
| Retained Earnings | -$84.3M | -$113.4M | -$167.1M | -$215.2M | -$275.0M | -$309.6M | -$350.6M | -$429.1M | -$559.5M | -$626.3M |
| Total Equity | -$18.2M | -$33.7M | $18.7M | $34.9M | $71.1M | $65.3M | $90.4M | $47.3M | $77.3M | $44.7M |
| Total Debt | $8.7M | $22.1M | $12.8M | $24.4M | $17.1M | $16.1M | $24.5M | $49.5M | $122.4M | $197.9M |
| Net Debt | $7.2M | $18.7M | -$26.8M | -$31.4M | -$48.2M | -$41.4M | -$68.8M | -$34.1M | -$54.1M | $7.2M |
| Working Capital | -$8.9M | -$25.0M | $31.8M | $39.5M | $54.3M | $53.9M | $91.0M | $71.3M | $143.3M | $54.9M |
Financial Health
| Debt / Equity | 0.66 |
| Current Ratio | 2.31 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 3.78 |
Profitability
| Return on Equity | 149.64% |
| Return on Invested Capital | 46.86% |
| Return on Assets | 26.56% |
| Gross Margin | 92.48% |
| Operating Margin | 37.39% |
| Net Margin | 30.74% |
Related companies: INSM · UTHR · RPRX · 0I3Q.L · CORT · KNSA · 0HF9.L · PBH
Explore sector: Healthcare · Medical - Pharmaceuticals
More sections of LQDA: Overview · Financials · Valuation · Estimates · Technical
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks